Fiagon AG Medical Technologies is now part of Intersect ENT – Click here to learn more about our navigation offering

Investor Relations

News

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Announces Preliminary Revenue for Third Quarter of 2020
Preliminary Third Quarter 2020 Revenue Expected to be $22.4 to $22.8 Million MENLO PARK, Calif. --(BUSINESS WIRE)--Oct. 15, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced preliminary third quarter
View HTML
Toggle Summary Intersect ENT to Report Third Quarter 2020 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Oct. 9, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it will release third quarter 2020 financial results on November 2, 2020 .
View HTML
Toggle Summary Intersect ENT Closes Acquisition of Fiagon AG Medical Technologies
MENLO PARK, Calif. & BERLIN --(BUSINESS WIRE)--Oct. 2, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced it closed the previously announced transaction to acquire Fiagon AG Medical Technologies , a
View HTML
Toggle Summary Intersect ENT Announces Agreement to Acquire Fiagon AG Medical Technologies for €60 Million Paid Over Three Years
Novel navigation technology and recently FDA-cleared sinuplasty balloon expand Intersect ENT’s commercial product portfolio Extends Intersect ENT’s footprint in U.S. and European ENT physicians’ offices MENLO PARK, Calif. and BERLIN --(BUSINESS WIRE)--Sep. 15, 2020-- Intersect ENT, Inc.
View HTML
Toggle Summary Intersect ENT Announces Specialty Pharmacy Partnership Agreement with AllianceRx Walgreens Prime to Distribute SINUVA® Sinus Implant View HTML
Toggle Summary Intersect ENT Reports Second Quarter 2020 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 4, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today reported financial results for the second quarter ended June 30, 2020 .
View HTML
Toggle Summary Intersect ENT to Report Second Quarter 2020 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Jul. 22, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it will release second quarter 2020 financial results on August 4, 2020 .
View HTML
Toggle Summary Intersect ENT Announces Independent Analysis in UK Confirming Cost Effectiveness of PROPEL® Steroid Releasing Sinus Implant Following Sinus Surgery for Chronic Sinusitis
Toggle Summary CMS Approves SINUVA® Sinus Implant for Reimbursement with New C‐Code and Pass‐Through Payment Status
Toggle Summary Intersect ENT to Present at the William Blair 40th Annual Growth Stock Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--May 26, 2020-- Intersect ENT, Inc. (Nasdaq: XENT ), today announced that management will participate in a virtual fireside chat at the William Blair 40 th Annual Growth Stock Conference . The fireside chat will take place on Thursday, June 11, 2020 at 8:00 a.m.
View HTML